NASDAQ:SMMT Summit Therapeutics Q2 2025 Earnings Report $17.60 +0.47 (+2.74%) As of 04:00 PM Eastern ProfileEarnings HistoryForecast Summit Therapeutics EPS ResultsActual EPS-$0.76Consensus EPS -$0.10Beat/MissMissed by -$0.66One Year Ago EPSN/ASummit Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ASummit Therapeutics Announcement DetailsQuarterQ2 2025Date8/11/2025TimeBefore Market OpensConference Call DateMonday, August 11, 2025Conference Call Time7:00AM ETUpcoming EarningsSummit Therapeutics' Q3 2026 earnings is estimated for Monday, October 19, 2026, based on past reporting schedules, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Summit Therapeutics Earnings HeadlinesSummit Therapeutics: The High Stakes Of Translating China Clinical Data To The U.S.September 3 at 11:11 PM | seekingalpha.comSummit packs a punch for Merck's Keytruda — but not everyone is soldSeptember 3 at 6:11 PM | msn.comThe ultimate IPO unicorn before Labor DayAnthropic is now valued at over $1 trillion, more than every U.S. airline combined and larger than the U.S. defense budget. Its annualized revenue grew 80x in the first quarter, and an IPO could arrive as early as October. For a limited time, investors can access a report detailing how to explore a pre-IPO stake in Anthropic for $29, a 94% discount off the retail price. The package includes a year of Disruptors and Dominators, monthly stock ideas, and four special reports.September 4 at 1:00 AM | Weiss Ratings (Ad)Summit Therapeutics Stock Rises 11%September 3 at 1:01 PM | rttnews.comBetter cancer therapy than Keytruda? Summit Therapeutics partner's Ivonescimab outperforms in lung cancer studySeptember 3 at 1:01 PM | msn.comNovember 14 Is The Make-Or-Break Moment For Summit Therapeutics' Cancer BetSeptember 3 at 7:00 AM | seekingalpha.comSee More Summit Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Summit Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Summit Therapeutics and other key companies, straight to your email. Email Address About Summit TherapeuticsSummit Therapeutics (NASDAQ:SMMT) is a clinical‐stage biotechnology company dedicated to the discovery and development of precision medicines for serious and life‐threatening diseases. The company applies a targeted approach to drug design, focusing on novel mechanisms of action that differentiate its candidates from existing therapies. Summit’s lead asset, ridinilazole (formerly SMT19969), is being developed to treat Clostridioides difficile infections and has received both Fast Track and Qualified Infectious Disease Product designations from the U.S. Food and Drug Administration. Alongside its infectious disease program, Summit has explored small‐molecule therapies for rare genetic disorders, leveraging its drug discovery capabilities to identify compounds that modulate disease‐relevant pathways. Founded in 2003 and headquartered in Oxford, England, Summit maintains operations in North America to support clinical development and regulatory activities across the United States and Europe. The company’s management team brings extensive experience in biopharmaceutical research, clinical operations, and commercialization strategy, with a commitment to advancing its pipeline toward regulatory approval and broad patient access.View Summit Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Snowflake’s AI Momentum Is Forcing a Fresh Look at the StockAeroVironment’s $465 Million Army Laser Win Expands Its Counter-Drone OpportunityFB Financial's Southern Expansion and Buybacks Drive Analyst OptimismRetail Earnings Just Exposed a Bigger Divide in the U.S. Consumer EconomyAccelerant’s Take-Private Deal Raises a Bigger Question for Insurance StocksDefense Stocks Are Pulling Back as Their Navy Tailwinds Get StrongerThe Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story Upcoming Earnings Adobe (9/10/2026)Oracle (9/10/2026)FedEx (9/17/2026)Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
